Mumbai, Nov. 12 -- Weight-loss and diabetes drugs such as semaglutide and liraglutide are expected to drive near-term growth in Biocon Ltd's generics business, chief executive and managing director Siddharth Mittal told Mint on Wednesday.

The Bengaluru-based company is banking on its expertise in the segment, as well as its existing partnerships in various markets and vertical integration, to capture a significant share of the fast-growing global market. "We know what it takes to bring such complex drugs to the market," the CEO said.

The biopharmaceutical major's generics business contributed 18% to overall revenue, rising 24% year-on-year to Rs.774 crore in the September quarter, driven by recent launches, especially liraglutide, in th...